DHL Adds Six Cold Chain Corridors Linking US Hub to Asia Pharma Markets

DHL Global Forwarding has activated six bi-directional cold chain corridors connecting North America and Europe to Asian healthcare and pharmaceutical hubs, according to an Oct. 12 press release. The move extends the carrier's Health Logistics Cold Chain Network into the trans-Pacific pharmaceutical trade, where temperature-controlled capacity and routing flexibility now decide who wins freight from high-value shippers.

The three new U.S.-based corridors run from DHL's Cincinnati/Northern Kentucky hub (CVG) to Singapore (SIN), Tokyo Narita (NRT) and Seoul Incheon (ICN). For pharmaceutical shippers, that means more routing options, reliable access to temperature-controlled capacity and steadier transit times across markets — the practical levers that reduce supply chain risk when a delayed vaccine shipment can scrap an entire batch.

What's behind the corridor buildout?

Customer demand, plainly. DHL Freight spokesperson Laura Lehnen told Supply Chain Dive the corridors respond to shipper calls for reliable pharmaceutical connectivity between healthcare markets. DHL launched a Brussels (BRU)-CVG route earlier this year as part of the same cold chain network, so the Asia expansion is the second leg of a deliberate infrastructure play rather than a one-off route announcement.

The Health Logistics Cold Chain Network itself is a global grid of dedicated healthcare corridors built for temperature-sensitive goods: pharmaceuticals, biologics, vaccines and clinical trial materials. The pitch rests on specialized handling processes and compliant infrastructure, which matters for shippers moving products governed by Good Distribution Practice rules.

Where is the volume actually heading?

Here's the detail practitioners should note: the flows aren't symmetrical. Lehnen said DHL is seeing stronger demand from pharmaceutical manufacturing hubs in North America and Europe toward Asia, so most of the corridors' available air freight capacity is dedicated to inbound Asia Pacific trade flows.

"DHL can therefore support both directions of trade as customer demand evolves and manufacturing and distribution patterns continue to develop," Lehnen said. Translation: the carrier is provisioning for today's eastbound-weighted volumes while keeping the network flexible if manufacturing footprints shift — a real possibility given continued pharma capacity buildup across Asian markets.

How does DHL move this freight?

Most of the routes fly on DHL's Boeing 777 freighter fleet, and the aircraft carry three separate compartments with dedicated temperature settings. That compartmentalization lets one flight carry shipments at different temperature bands simultaneously — a capacity economics advantage on lanes where pharma volumes don't always fill a full temperature-controlled payload in a single band.

On the ground, Cincinnati anchors the operation. Lehnen described CVG as one of DHL's established healthcare gateways, offering temperature-controlled storage and handling, GDP-compliant healthcare logistics facilities and specialized equipment. DHL also operates a dedicated life sciences and healthcare facility in Indianapolis, giving the network two U.S. infrastructure nodes.

What's next at Cincinnati?

DHL is layering further investment onto the CVG gateway, and the timeline is concrete:

• Near future: five temperature-controlled dollies to move healthcare shipments between aircraft and facilities during extreme weather, closing a gap where tarmac transfer can break the cold chain.
• 2027: a new airside facility providing temperature-controlled storage for inbound and outbound Unit Load Devices (ULDs) near the aircraft, preserving temperature integrity through the handling process.
• Ongoing: a new off-airport facility with temperature-controlled storage and handling, including ULD build-up and break-down capabilities plus pallet storage.

The 2027 airside facility is the structural piece. Positioning ULD storage next to aircraft shortens the exposure window that pharma shippers worry about most — the minutes between climate-controlled warehouse and climate-controlled hold.

Is the competition standing still?

No. FedEx launched a dedicated organization for healthcare and pharmaceutical logistics in June, and last year it began flying a Dublin (IND) route — technically Dublin (DUB) to Indianapolis — aimed primarily at healthcare goods. FedEx anchoring its own healthcare lane on Indianapolis mirrors DHL's dual CVG-Indianapolis footprint, which signals both integrators see the same Midwest pharma geography as the U.S. fulcrum for temperature-controlled air freight.

For shippers and forwarders, the practical takeaway is capacity depth: three carriers' worth of dedicated pharma infrastructure now competes on trans-Atlantic and trans-Pacific healthcare lanes, which pressures transit reliability and service differentiation more than headline rates. DHL's bet is that corridor-level control of the full chain — aircraft compartments, dollies, airside ULD storage — becomes the deciding factor as Asia-bound and Asia-origin pharma volumes keep growing.